Adaptive Biotechnologies is well positioned in the growing field of immune-driven medicine and has a strong financial outlook.
Bears say
Adaptive Biotechnologies is showing strong revenue growth and expanding margins, particularly in its Minimal Residual Disease segment driven by increasing penetration of its clonoSEQ test. However, the company's valuation is currently near 5-year highs and there are potential risks to the medical and life science tools sector that could impact the company's future performance. Additionally, while the company plans to separate its Immune Medicine business from its core MRD business by the end of 2026, there is no guarantee this will occur as planned.
Adaptive Biotechnologies (ADPT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Get the latest Adaptive Biotechnologies (ADPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
FAQs About Adaptive Biotechnologies (ADPT) Forecast
Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.
According to 6 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $24.42, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $24.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest Adaptive Biotechnologies (ADPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.